Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha.

No abstract is available for this paper.

• Publication year

  1996

• Venue

  Annals of Oncology

• Publication date

  1996-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/OXFORDJOURNALS.ANNONC.A010762PMID 8922197
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2.

  1994cited by this paper
• Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma.

  1994cited by this paper
• Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma.

  1994cited by this paper
• A phase II trial of concomitant human interleukin-2 and interferon-alpha-2a in patients with disseminated malignant melanoma.

  1993cited by this paper
• Inpatient continuous‐infusion interleukin‐2 in 788 patients with cancer the national biotherapy study group experience

  1993cited by this paper
• Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma.

  1993cited by this paper
• Interferon-alpha and interleukin-2 in the treatment of metastatic melanoma. Comparison of two phase II trials.

  1993cited by this paper
• Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma.

  1993cited by this paper
• A phase II study of dacarbazine and cisplatin in combination with outpatient administered interleukin‐2 in metastatic malignant melanoma

  1993cited by this paper
• Interferon‐α and interleukin‐2 in the treatment of metastatic melanoma. Comparison of two phase II trials

  1993cited by this paper
• Sequential chemoimmunotherapy in the treatment of metastatic melanoma.

  1992cited by this paper
• Effective combination chemo/hormonal therapy for malignant melanoma: Experience with three consecutive trials

  1992cited by this paper
• Sequential chemoimmunotherapy for metastatic melanoma.

  1991cited by this paper
• Interleukin-2 and high-dose cisplatin in patients with metastatic melanoma: a pilot study.

  1991cited by this paper
• A phase I‐II study of dacarbazine in combination with outpatient interleukin‐2 in metastatic malignant melanoma

  1990cited by this paper
• Interleukin-2 therapy in patients with metastatic malignant melanoma: a phase II study.

  1990cited by this paper
• Concomitant administration of recombinant human interleukin-2 and recombinant interferon alpha-2A in cancer patients: a phase I study.

  1989cited by this paper
• Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer.

  1989cited by this paper
• A prospective evaluation of a triple‐drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma

  1989cited by this paper
• Recombinant leukocyte A interferon (rlFN-aA) in the treatment of disseminated malignant melanoma

  1987cited by this paper
• Interferons in the treatment of malignant melanoma

  1987cited by this paper
• Clinical evaluation of recombinant interferon alfa-2a (Roferon-A) in metastatic melanoma using two different schedules .

  1987cited by this paper
• Recombinant leukocyte a interferon (rIFN‐αA) in the treatment of disseminated malignant melanoma: Analysis of complete and long‐term responding patients

  1986cited by this paper
• Interferons in the treatment of malignant melanoma. A review of recent trials

  1986cited by this paper

• Exploring Anticancer Potential of Camptothecin Isolated from Nothapodytes Nimmonianain the Treatment of Prostate and Lung Carcinoma

  2024cites this paper
• Mucosal melanoma: from molecular landscape to current treatment strategies

  2023cites this paper
• Targeted nanoscale drug delivery systems for melanoma therapy

  2023cites this paper
• Educational Review: Clinical Application of Immune Checkpoint Blockade for the Treatment of Melanoma

  2023cites this paper
• Anaphylactic reaction to carboplatin diagnosed by skin testing—a reliable tool in platinum-based immediate-type hypersensitivity reactions

  2022cites this paper
• Reprogramming of T cell‐derived small extracellular vesicles using IL2 surface engineering induces potent anti‐cancer effects through miRNA delivery

  2022cites this paper
• Current Drug Delivery Strategies for Buccal Cavity Ailments using Mouth Dissolving Wafer Technology: A Comprehensive Review on the Present State of the Art.

  2022cites this paper
• Recurrence Patterns for Regionally Metastatic Melanoma Treated in the Era of Adjuvant Therapy: A Systematic Review and Meta-Analysis

  2022cites this paper
• Metastatic melanomas: Treatment overview

  2021cites this paper
• Chimeric antigen receptor T-cell therapy for melanoma

  2021cites this paper
• Caffeine improves the cytotoxic effect of dacarbazine on B16F10 murine melanoma cells.

  2021cites this paper
• Metastatic melanoma-A review of current and future perspective

  2020cites this paper
• Design and characterization of camptothecin gel for treatment of epidermoid carcinoma

  2020cites this paper
• Metastasis: A Major Driver of Cancer Pathogenesis

  2020cites this paper
• Drug Targets in Cellular Processes of Cancer: From Nonclinical to Preclinical Models

  2020cites this paper
• Effect of carboplatin when administered after dacarbazine failure: Clinical benefit of sequential therapy.

  2020cites this paper
• Update on BRAF and MEK inhibition for treatment of melanoma in metastatic, unresectable, and adjuvant settings

  2019cites this paper
• The emergence of neoadjuvant therapy in advanced melanoma

  2019cites this paper
• Sequencing Ipilimumab Immunotherapy Before or After Chemotherapy (Nab-Paclitaxel and Bevacizumab) for the Treatment of BRAFwt (BRAF Wild-Type) Metastatic Malignant Melanoma

  2019cites this paper
• WITHDRAWN: Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma.

  2018cites this paper
• Diagnosis, Prognosis and Management of Incidental Metastatic Melanoma to Breast, Axilla and Regional Lymph Nodes in a Ninety-Year-Old Female

  2018cites this paper
• Methylation of O6-methylguanine DNA methyltransferase promoter is a predictive biomarker in Chinese melanoma patients treated with alkylating agents

  2018cites this paper
• Clinical Response Rates From Interleukin-2 Therapy for Metastatic Melanoma Over 30 Years’ Experience: A Meta-Analysis of 3312 Patients

  2017cites this paper
• Affinity Gradient of Chimeric Antigen Receptor T-Cells Against Low-Antigen Density Target

  2017cites this paper
• Recent Advances in Hydrogel-Based Drug Delivery for Melanoma Cancer Therapy: A Mini Review

  2017cites this paper
• Chemotherapy for Melanoma.

  2016cites this paper
• Adoptive cell transfer: examining the potential of a T cell-mediated therapy for metastatic melanoma

  2016cites this paper
• MECHANISMS OF MELANOMA DRUG RESISTANCE

  2015cites this paper
• Immune Effects of Chemotherapy, Radiation, and Targeted Therapy and Opportunities for Combination With Immunotherapy.

  2015cites this paper
• Predictive biomarkers to chemotherapy in patients with advanced melanoma receiving the combination of cisplatin--vinblastine--temozolomide (PVT) as first-line treatment: a study of the Hellenic Cooperative Oncology Group (HECOG).

  2015cites this paper
• Drivers of melanoma susceptibility

  2015cites this paper
• BRAF and MEK inhibition in melanoma

  2015cites this paper
• New Strategies in Melanoma: Entering the Era of Combinatorial Therapy

  2015cites this paper
• Systemic treatments for metastatic cutaneous melanoma.

  2014cites this paper
• Targeting the PD1/PD-L1 axis in melanoma: biological rationale, clinical challenges and opportunities.

  2014cites this paper
• No longer an untreatable disease: How targeted and immunotherapies have changed the management of melanoma patients

  2014cites this paper
• Surveillance for brain metastases in patients receiving systemic therapy for advanced melanoma

  2014cites this paper
• Novel dendritic cell-based vaccination in late stage melanoma

  2014cites this paper
• Novel alpha-MSH peptide analogs for melanoma targeting

  2014cites this paper
• AVALIAÇÃO IN VITRO DOS EFEITOS CITOTÓXICOS E ANTIMETASTÁTICOS DE SAIS DE ISOTIOURÔNIO, DE N- FENILISOTIOURÔNIO E DE ISOTIOSSEMICARBAZIDAS EM LINHAGENS DE MELANOMA

  2014cites this paper
• Cooperation of p300 and iASPP in apoptosis and tumour suppression

  2014cites this paper
• Surgical and radiation therapy management of recurrent anal melanoma.

  2014cites this paper
• Latest advances in chemotherapeutic, targeted, and immune approaches in the treatment of metastatic melanoma.

  2014cites this paper
• State of melanoma: an historic overview of a field in transition.

  2014cites this paper
• Current Therapies and New Pharmacologic Targets for Metastatic Melanoma

  2013cites this paper
• Chemotherapy in the management of advanced cutaneous malignant melanoma.

  2013cites this paper
• Combination and Sequencing of Therapies for the Treatment of Metastatic Melanoma

  2013cites this paper
• Pharmacotherapy of metastatic melanoma: emerging trends and opportunities for a cure.

  2013cites this paper
• Metastatic melanoma in the older patient: special considerations.

  2013cites this paper
• Comparison of two dosing schedules of palonosetron for the prevention of nausea and vomiting due to interleukin-2-based biochemotherapy

  2012cites this paper
• NCCN Melanoma Clinical Practice Guidelines in Oncology

  2012cites this paper
• Aldesleukin (Recombinant Interleukin-2)

  2012cites this paper
• Tubeimoside-1 inhibits growth via the induction of cell cycle arrest and apoptosis in human melanoma A375 cells

  2012cites this paper
• Sensitization to the mitochondrial pathway of apoptosis augments melanoma tumor cell responses to conventional chemotherapeutic regimens

  2012cites this paper
• Managing immune-related adverse events to ipilimumab: a nurse's guide.

  2012cites this paper
• Molecular targeted therapy in melanoma: a way to reverse resistance to conventional drugs.

  2012cites this paper
• MelanomaPractice Guidelines in Oncology

  2012cites this paper
• Melanoma colorrectal: revisión de dos formas diferentes de presentación

  2011cites this paper
• Does complete response to systemic therapy in patients with stage IV melanoma translate into long-term survival?

  2011cites this paper
• Prognostic factors for survival in melanoma patients with brain metastases

  2011cites this paper
• Born to be Alive: A Role for the BCL-2 Family in Melanoma Tumor Cell Survival, Apoptosis, and Treatment

  2011cites this paper
• Prospective evaluation of supportive care with or without CVD chemotherapy as a second-line treatment in advanced melanoma by patient’s choice: a multicentre Dermatologic Cooperative Oncology Group trial

  2011cites this paper
• [Colorectal melanoma: review of two distinct forms of presentation].

  2011cites this paper
• Eupatilin: A flavonoid compound isolated from the artemisia plant, induces apoptosis and G2/M phase cell cycle arrest in human melanoma A375 cells

  2011cites this paper
• Cytokine therapy in melanoma

  2010cites this paper
• Concurrent chemoimmunotherapy: is it still the best option for the treatment of metastatic melanoma in patients with good performance status?

  2010cites this paper
• Unexpected High Response Rate to Traditional Therapy after Dendritic Cell-Based Vaccine in Advanced Melanoma: Update of Clinical Outcome and Subgroup Analysis

  2010cites this paper
• Systemic therapy for cutaneous melanoma.

  2010cites this paper
• Erratum to “Unexpected High Response Rate to Traditional Therapy after Dendritic Cell-Based Vaccine in Advanced Melanoma: Update of Clinical Outcome and Subgroup Analysis”

  2010cites this paper
• Biochemotherapy in the treatment of metastatic melanoma in selected patients.

  2009cites this paper
• New perspectives for melanoma immunotherapy: role of IL-12.

  2009cites this paper
• Chemotherapy and biologic therapies for melanoma: do they work?

  2009cites this paper
• A randomized phase III trial of biochemotherapy versus interferon-&agr;-2b for adjuvant therapy in patients at high risk for melanoma recurrence

  2009cites this paper
• Biochemotherapy in the treatment of metastatic melanoma in selected patients

  2009cites this paper
• Phase II multicenter trial of maintenance biotherapy after induction concurrent Biochemotherapy for patients with metastatic melanoma.

  2009cites this paper
• Metastatic malignant melanoma.

  2009cites this paper
• Emerging strategies to strengthen the anti-tumour activity of type I interferons: overcoming survival pathways.

  2009cites this paper
• Phase I/II Study of a Cisplatin-Taxol-Dacarbazine Regimen in Metastatic Melanoma

  2009cites this paper
• Phase I study of the combination of docetaxel, temozolomide and cisplatin in patients with metastatic melanoma

  2009cites this paper
• HSPPC-96 vaccine in metastatic melanoma patients: from the state of the art to a possible future

  2009cites this paper
• Treatment of metastatic melanoma: an overview.

  2009cites this paper
• Treatment of melanoma and nonmelanoma skin cancer.

  2008cites this paper
• Interleukin-2-Based Biochemotherapy for Patients with Stage IV Melanoma: Long-Term Survivors Outside a Clinical Trial Setting

  2008cites this paper
• Conjunctival Melanoma in Finland 1967-2000: a population-based study

  2008cites this paper
• Systemic Therapy for Unresectable Metastatic Melanoma: Impact of Biochemotherapy on Long-Term Survival

  2008cites this paper
• Biochemotherapy in patients with advanced head and neck mucosal melanoma

  2008cites this paper
• Prognostic Factors That Determine the Long-Term Survival of Patients with Unresectable Metastatic Melanoma

  2008cites this paper
• Management of metastatic melanoma.

  2007cites this paper
• Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma.

  2007cites this paper
• Comparison Among Clark's, Breslow's, and TNM Classifications for Cutaneous Head and Neck Malignant Melanoma

  2007influential citation
• Biochemotherapy of metastatic melanoma in patients with or without recently diagnosed brain metastases

  2007cites this paper
• Systemic therapy of disseminated malignant melanoma: an evidence‐based overview of the state‐of‐the‐art in daily routine

  2007cites this paper
• Complex combination biochemotherapy regimen in advanced metastatic melanoma in a non-intensive care unit: toxicity or benefit?

  2007influential citation
• Malignant melanoma in the 21st century, part 2: staging, prognosis, and treatment.

  2007cites this paper
• The molecular mechanisms of vitamin C on cell cycle regulation in B16F10 murine melanoma

  2007cites this paper
• Combination Cytokine Therapy

  2007cites this paper
• [Therapy of malignant melanoma. First-, second- and pathogenesis-oriented third-line therapies].

  2006cites this paper
• Anal Melanoma

  2006cites this paper
• CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma.

  2006cites this paper
• Management of metastatic melanoma 2005.

  2006cites this paper